行情

PLX

PLX

PROTALIX生物疗法
AMEX

实时行情|Nasdaq Last Sale

2.050
+0.020
+0.99%
盘后: 2.050 0 0.00% 19:26 06/17 EDT
开盘
2.050
昨收
2.030
最高
2.090
最低
2.020
成交量
178.11万
成交额
--
52周最高
7.02
52周最低
2.000
市值
9,303.48万
市盈率(TTM)
-5.2821
分时
5日
1月
3月
1年
5年
PLX:余额:中期业绩
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT
Benzinga · 06/08 13:40
周一触及 52 周低点的股票
    Before 10 a.m. ET Monday, 8 stocks made new 52-week lows.
Benzinga · 06/07 14:05
Protalix Bio Therapeutics 股票的重大内幕交易
MT Newswires · 06/04 22:29
周五触及 52 周低点的股票
    On Friday morning, 7 companies hit new 52-week lows.
Benzinga · 06/04 14:04
内幕趋势:内幕增加了 Protalix Bio Therapeutics 的 90 天销售趋势
MT Newswires · 06/03 17:58
在 PRX-102 法布里病试验报告不良事件后,Protalix 股价跌至 52 周低点
Benzinga · 06/02 16:10
Protalix Biotherapeutics 和 Chiesi Global Rare Diseases 提供有关 PRX-102治疗法布里病临床开发的最新信息
Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary
Benzinga · 06/02 10:51
PLX:1Q:21结果和后续步骤
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT
Benzinga · 05/30 11:20
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解PLX最新的财务预测,通过PLX每股收益,每股净资产,每股现金流等数据分析PROTALIX生物疗法近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测PLX价格均价为9.75,最高价位12.50,最低价为7.00。
EPS
机构持股
总机构数: 32
机构持股: 1,241.20万
持股比例: 27.35%
总股本: 4,538.28万
类型机构数股数
增持
6
151.35万
建仓
7
167.01万
减持
3
8.92万
平仓
9
23.20万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.60%
制药与医学研究
+0.27%
高管信息
Chairman/Director
Zeev Bronfeld
President/Chief Executive Officer/Director
.. ..
President/Chief Executive Officer/Director
Dror Bashan
Chief Financial Officer/Senior Vice President
Eyal Rubin
Senior Vice President
Einat Almon
Senior Vice President
Yaron Naos
Vice President - Research & Development
Yael Hayon
Director
Pol Boudes
Director
Gwen Melincoff
Independent Director
Amos Bar-Shalev
Independent Director
David Granot
Independent Director
Aharon Schwartz
暂无数据
PLX 简况
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.

微牛提供Protalix Biotherapeutics Inc(AMEX-PLX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PLX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PLX股票基本功能。